Work

Reversal strategies for non-vitamin K antagonist oral anticoagulants: a critical appraisal of available evidence and recommendations for clinical management—a joint position paper of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Working Group on Thrombosis

Year: 2015
Type: article
Abstract: Bleeding is the main adverse effect when using oral anticoagulants (OACs). The risk of major bleeding with vitamin K antagonists (VKAs) is dependent on the quality of anticoagulation control and estimated to be ∼1.3/100 patients/year in patients with INR 2.0–3.0.1,2 Multiple limitations of VKAs stimulated the development of non-vitamin K antagonist oral anticoagulants (NOACs) acting directly on coagulation factors, including factor FIIa (thrombin) and FXa. Pharmacological properties of the NOACs relevant for bleeding are summarized in the supplement including Supplementary material online, Table S1 and their main effects are summarized in Supplementary material online, Table S2. The risk of bleeding in patients managed with NOACs was properly assessed in the four landmark Phase III trials in patients with atrial fibrillation (AF; Table 1). Major bleeding was the principal safety outcome in RE-LY,3,4 ARISTOTLE,5 and ENGAGE AF.6 In ROCKET-AF, the primary safety endpoint was the composite of major and non-major clinically relevant bleeding.7 The risk of major bleeding was significantly reduced with dabigatran 110 mg b.i.d., apixaban and both doses of edoxaban3–6 while the bleeding rates for dabigatran 150 mg b.i.d. and rivaroxaban were similar to those with warfarin (Table 1). Risk of bleeding with non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation (rates per 100 patients-years) These data derive from separate studies comparing each NOAC to VKA; there are no head-to-head studies between NOACs. b.i.d., twice daily; o.d., once daily; GI, gastrointestinal; ICH, intracranial haemorrhage; NA, not applicable; NMCR, non-major clinically relevant. Risk of bleeding with non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation (rates per 100 patients-years) These data derive from separate studies comparing each NOAC to VKA; there are no head-to-head studies between NOACs. b.i.d., twice daily; o.d., once daily; GI, gastrointestinal; ICH, intracranial haemorrhage; NA, not applicable; NMCR, non-major clinically relevant. Gastrointestinal (GI) bleeding accounts for ∼90% of major extracranial haemorrhages in patients with AF receiving VKAs.8 With the NOACs, dabigatran 150 mg b.i.d., rivaroxaban, and edoxaban 60 mg o.d. significantly increased rates of GI bleeding (∼1.5-fold) compared with warfarin.3,6,7 While rivaroxaban increases upper and lower GI bleeding to a similar extent, dabigatran 150 mg b.i.d. prominently increased lower GI bleeding.9 Apixaban was associated with GI bleeding rates comparable with those with warfarin.5 Edoxaban 30 mg o.d. demonstrated significantly lower rates of GI bleeding compared with warfarin (Table 1).6 Intracranial haemorrhage (ICH) is the major concern in patients on OACs and this is the field where NOACs demonstrated major clinical improvement (Table 1). In the four trials, the hazard ratio for ICH was between 0.31 and 0.64, with meta-analysis showing a hazard ratio of 0.48 overall.10 Furthermore, the sequelae of ICH may be less severe when it has occurred during NOAC treatment.11 Major bleeding and ICH rates in ‘real-world’ post-marketing data for NOACs also seems to be generally reassuring, although GI bleeding rates appear to be higher for dabigatran (150 mg b.i.d.) compared with warfarin.12–14 While this paper focuses on the reversal of the effects of NOACs due to an emergency situation, prevention of bleeding remains of utmost importance. The risk of bleeding may be estimated using the well-validated HAS-BLED score.15 A high HAS-BLED score is there to ‘flag up’ patients at higher risk of bleeding for more careful review and follow-up, as well as attention to the potentially reversible risk factors for bleeding, such as uncontrolled hypertension (systolic blood pressure >160 mmHg), labile INRs (for VKA user), concomitant use of aspirin/NSAIDs, alcohol excess. Among AF patients, the HAS-BLED score has been validated to be predictive of bleeding with VKAs, aspirin, and NOACs.16–19 The need to reverse the effect of NOACs occurs in case of life-threatening bleeding, bleeding which cannot be controlled by withdrawal of OAC and usual care, or medical emergencies other than bleeding requiring immediate surgery (Figure 1). Intracranial haemorrhage, with the highest likelihood for fatal outcome, is one of the primary aims for reversal agents. A timely administration of reversal agents is likely to be of major relevance for an improved clinical outcome in case of ICH. However, bleeding at other sites may also be life-threatening and risk stratification is more difficult but essential for these bleeding events. A subanalysis of the RE-LY trial showed that attempts to reverse the effect of dabigatran with clotting factor concentrates (CFCs) were observed in <2% of all major bleeding events.20 Despite the lack of a specific reversal agent, patients in the NOAC arm showed a trend for reduced mortality associated with major bleeding compared with VKA, most likely due to a shorter half-life and a lower rate of ICH.20,21 At the present time, available guidance for reversal of uncontrolled bleeding in patients treated with NOACs is based on expert opinion rather than on clinical trials.22–25 Practical management of the reversal of non-vitamin K antagonist oral anticoagulants. *: requiring normal haemostasis (for other conditions than bleeding); **: when approved by respective regulatory authorities; idarucizumab has been approved for reversal of the effect of dabigatran by the European Medicines Agency and the U.S. Food and Drug Administration; ***: antagonization of concomitant anti-platelet therapy: • Reconsider combination therapy and hold off anti-platelet therapy until safe/appropriate to restart. • Consider platelet transfusion if receiving irreversible anti-platelet drug (aspirin, clopidogrel, and prasugrel) or thrombocytopenia. • Consider specific antidote (MEDI2452) if receiving ticagrelor and when antidote approved by respective regulatory authorities and available. As there are no specific antidotes available so far, several therapeutic interventions have been used, including activated charcoal, haemodialysis, activated charcoal haemoperfusion, fresh frozen plasma (FFP), and pro-haemostatic agents.22–25 This section will focus on the potential of the pro-haemostatic CFCs for reversal of NOAC effects encompassing pro-thrombin complex concentrates (PCCs) and recombinant (r)FVIIa (Novoseven®, NiaStase©). The ESC Guidelines for the management of AF have recommended considering these CFCs in case of very severe bleeding.26 Pro-thrombin complex concentrates, developed for reversal of VKAs, are lyophilized concentrates of vitamin K-dependent coagulation factors available as: (i) non-activated three-factor PCCs (Profilnine® SD, Bebulin® VH) containing similar amounts of factors II, IX, and X, and low factor VII levels; (ii) non-activated four-factor PCCs (Beriplex® P/N, Kanokad®, Octaplex®, Kaskadil®, Cofact®), containing adequate levels of factors II, VII, IX, and X, with varying amounts of heparin and proteins C and S to reduce thrombogenicity; and (iii) activated four-factor PCC (FEIBA®) containing factors II, IX, X, and protein C, mainly in non-activated forms, and factor VII mainly in the activated form. rFVIIa is a potent general haemostatic agent.27,28 Fresh frozen plasmas containing normal levels of all coagulation factors have practical constraints for the rapid reversal of OACs. A limitation for the use of PCCs is an absolute increase of thromboembolic events of >1%.29,30 The increase of thromboembolic events associated with the use of rFVIIa may be even higher.31,32 As the effect of pro-haemostatic agents on NOACs has not been tested in clinical trials so far, our evidence is based on surrogate endpoints. In comparison, the effect of PCCs on the reversal of VKA effects has been evaluated in patients with major bleeding or requiring urgent surgery. However, this evidence is likewise based on the effect on coagulation tests in small, mostly uncontrolled, retrospective,33 and prospective clinical trials.34–37 In Supplementary material online, surrogate endpoints for measuring the reversal of NOAC effects with CFCs are critically appraised. Supplementary material online, Table S3 gives a detailed description of the available data for reversal of NOAC effects with CFCs based on normalization of coagulation tests, ex vivo thrombus generation (TG) or animal bleeding models. In summary, the evidence supporting the efficacy and safety of CFCs in case of severe or life-threatening bleeding is based on laboratory or animal studies, case reports and a Phase I trial using punch biopsies38 but not on well-designed clinical trials so far. The results are contradictory with regard to an overall reversal of NOAC effects by CFCs and the preference of one specific CFC. Furthermore, they are confusing due to the lack of correlation between the correction of routine laboratory tests, TG, and bleeding in animal models. In particular, animal data suggest that a high dose of CFCs (e.g. 50 IU/kg of four-factor PCC) is necessary for a sufficient reversal effect. Limited animal data suggest that CFCs may ameliorate the effect of NOACs in case of ICH. An important drawback of the use of PCCs and rFVIIa may be an increased risk of thromboembolic complications.29–32 Pending the availability of robust clinical evidence of a beneficial effect, if immediate haemostatic support is required due to a life-threatening situation, the choice of CFCs may be based on its least pro-thrombotic effect, favouring PCCs over rFVIIa. If a four-factor PCC is used, a high dose or repeated dose is recommended. Finally, the choice of a CFC must be individually assessed according to drug availability and experience of the centre, institutional transfusion guidelines and available consensus among cardiologists, haemostasis experts, and emergency physicians. Although pro-haemostatic agents may also limit the extent of bleeding in patients with ICH, their effect on mortality and disability is unknown.39 A number of new reversal agents are under development, including monoclonal antibodies, decoy receptors, and small molecules with high affinity for NOACs (Table 2). These agents aim to specifically, completely, and rapidly reverse the effect of NOACs (Figure 2). Another perceived advantage of these reversal agents is the lack of a pro-thrombotic effect of the agents themselves. However, the sole interruption of anticoagulation therapy may be associated with an increased risk of thromboembolic events. Accordingly, in Phase III trials for AF, an increased thromboembolic risk has been observed at the end of the study after study treatment has been stopped.7 Despite the assumed high efficiency of specific reversal agents, their effectiveness in preventing clinical events needs to be determined. Specifically, life-threatening situations with impairment of renal and liver function will constitute a challenge for improvement of survival by specific reversal of NOAC effects. New reversal agents for non-vitamin K antagonist oral anticoagulants The clinical development program for Ciraparantag is currently at the Phase II stage, it is not possible to comment on the dose that will be studied in the Phase III trial and which is therefore more likely to be approved for clinical use. New reversal agents for non-vitamin K antagonist oral anticoagulants The clinical development program for Ciraparantag is currently at the Phase II stage, it is not possible to comment on the dose that will be studied in the Phase III trial and which is therefore more likely to be approved for clinical use. Mechanism of non-vitamin K antagonist oral anticoagulants and their antidotes adapted from Enriquez et al.63 The prothrombinase complex, consisting of FXa and FIIa, catalyses the conversion of pro-thrombin (II) to thrombin (IIa), leading to fibrin generation and clot formation. The effect of the thrombin inhibitor dabigatran (dab) may be reversed by idarucizumab, a humanized antibody fragment against dabigatran OR ciraparantag, a small synthetic molecule competitively binding the non-vitamin K antagonist oral anticoagulants (A). The effect of the FXa inhibitors (a-Xa) apixaban, edoxaban and rivaroxaban may be reversed by andexanet alpha, a modified inactive recombinant FXa competitively binding circulating FXa inhibitors OR ciraparantag (B). Idarucizumab (BI 655075) is a humanized, highly selective, and specific monoclonal antibody fragment (fab) which binds dabigatran with high affinity (dissociation constant, KD, 2.1 pM), i.e. ∼350 times stronger than for thrombin. It rapidly (<5 min) and completely inhibited the anticoagulant activity of dabigatran in ex vivo human clotting tests (half maximal inhibitory concentration [IC50] of 2–5 nM) as well as in in vivo models, exerting a sustained effect for up to 6 h after intravenous (i.v.) injection.40 However, idarucizumab has no direct activity on coagulation or platelet aggregation.40,41 In Phase I placebo-controlled studies, ecarin clotting time (ECT) and diluted thrombin time (dTT) were significantly prolonged with dabigatran and reversed to control levels after i.v. dosing with idarucizumab (1, 2, 4, and 5 + 2.5 g) in 47 men.42 It was found to be safe and effective, in that dTT was almost immediately corrected.41,42 For the 1 g dose, there was partial return of dabigatran-induced anticoagulation accompanied by an increase of unbound dabigatran concentrations ∼2–4 h after i.v. infusion.42,43 Additionally, idarucizumab reversed dabigatran-induced inhibition of wound site fibrin formation.44 In another 46 male and female volunteers, 2.5–5 g of idarucizumab resulted in immediate, complete, and sustained reversal of dabigatran-induced anticoagulation. The reversal effect was consistent for elderly and renally impaired subjects [creatinine clearance (CrCl) 30 to <90 mL/min).43 Dabigatran anticoagulation could be re-established 24 h after idarucizumab dosing. An uncontrolled Phase III study (RE-VERSE AD) will assess for the reversal of the anticoagulant effects of dabigatran by the i.v. administration of 5 g of idarucizumab in dabigatran-treated patients, who have uncontrolled bleeding or require emergency surgery or procedures (NCT0210494).45 Up to 300 dabigatran-treated patients with uncontrollable overt bleeding in need of reversal as judged by the attending physician (group A), OR in need of emergency surgery or procedures within the first 4 h (group B) will be enrolled. Patients with bleeding manageable conservatively (group A) or requiring surgery where the risk of uncontrolled or unmanageable bleeding is low (group B) are excluded. The primary endpoint is the reversal of anticoagulant effect of dabigatran in the first 4 h with a specific coagulation or A first has been in patients The most bleeding events in A were GI bleeding and ICH patients were from as they normal coagulation tests at Idarucizumab rapidly and completely reversed the anticoagulant activity of dabigatran in of In the concentration of unbound dabigatran was reduced to a at or the lower limit of In patients, a of the effect of idarucizumab was observed after h and 24 h due to of dabigatran the These results reversal of the specific effect of dabigatran in critically patients who uncontrollable bleeding or who require emergency surgery while on With regard to clinical bleeding, haemostasis was after a of h in In normal haemostasis was observed in of However, this normalization of haemostasis not was observed within h after administration of idarucizumab and another four events after A controlled against or CFCs have been to assess the of the reversal on the clinical of the clinical of the trial patients, such a major The of the trial to the of idarucizumab by the European Medicines Agency and the U.S. Food and Drug a human recombinant is inactive and the of FXa but the of FXa to direct FXa inhibitors as well as III with for direct FXa It as a decoy and with the anticoagulant effects of all FXa reversed the inhibition of FXa activity by FXa inhibitors and clot ex In animal bleeding models, it reduced blood and haemostasis after with rivaroxaban as well as FXa inhibitors and The effect of with the in FXa inhibitor plasma levels and However, not with normal FXa function in haemostasis and not have anticoagulant In a Phase I study not on anticoagulant to be safe and well A placebo-controlled Phase II trial the reversal effect of after dosing to with direct and FXa inhibitors in of from to mg were for reversal of FXa A reversal of the anticoagulant effect was observed when measuring activity with a of A of mg for h the reversal effect. activity to levels h after the end of In plasma concentrations of unbound FXa inhibitors immediately after generation and clotting time were also reversed by or adverse events were However, factor inhibitor activity also due to its binding to These results suggest that has the potential to be a antidote for reversal of anticoagulation by direct and FXa In a was tested in measuring The first trial tested the reversal of apixaban 5 mg twice for 4 to mg i.v. showed a reversal and rapidly the anticoagulant effect of adverse events or events were In the will be as mg i.v. by a of 4 for In the trial the reversal of rivaroxaban will be tested in for reversal of edoxaban is A Phase III trial will the safety and of in the effect of inhibitors in patients with an major bleeding idarucizumab, this will be an uncontrolled, The primary endpoint will be the of patients with or Ciraparantag is a small molecule for the reversal of oral direct FXa and FIIa and but not the of are In ex vivo studies, completely reversed the anticoagulant activity of rivaroxaban and apixaban with activity in human effects were In treated with high doses of reduced blood in bleeding results were observed with rivaroxaban, apixaban, and In coagulation tests to levels within Additionally, no effects were In a liver the highest dose of and showed a similar of blood in with However, not activity in this A Phase I trial evaluated the and plasma and of a of i.v. doses of or a dose of mg reversed edoxaban 60 mg within and clot for 24 effects were In this first was safe and well An clinical trial the and effect on blood clotting time of intravenous doses of and after 60 mg edoxaban as a in and repeated for a to effects of on the with edoxaban and reversal with Phase III clinical trial results need to be to assess the clinical therapeutic potential of this new NOAC While controlled Phase III trials may not be in this of in an of evidence from studies will be even more of to be in studies (i) the risk of thromboembolic events in patients with immediate reversal of anticoagulation reversal agents a pro-thrombotic effect per (ii) the clinical of specific in patients with severe but not life-threatening bleeding or urgent (iii) the effect of specific reversal agents on clinical events with specific focus on and the effect of specific reversal agents in patients with and While available clinical data for specific antidotes of NOACs are it is very likely that these agents will reverse the effect of NOACs as by specific coagulation Another perceived advantage is the lack of a pro-thrombotic effect of the However, uncontrolled studies will not a to the the clinical outcome will be In the of specific CFCs for dabigatran may be a and may be in to specific reversal agents in case of liver or renal considering the use of a reversal for NOACs, a and clinical of the complex of a critically is essential (Table Furthermore, a of general the use of a reversal agent, as in While the availability of specific reversal agents will increase the in the of NOACs in clinical an of specific reversal agents the tested is of advantage for of bleeding in patients with NOACs by the bleeding risk of the and by and remains in patients who have life-threatening bleeding, anticoagulation therapy is associated with reduced of thromboembolic events and mortality the risk of a timely of anticoagulant therapy therapeutic such as atrial be on the and the of the bleeding of patients with a major bleeding or requiring emergency surgery of specific NOAC and dose dose function with estimated rate half-life of NOAC function and of anticoagulation or if not available pro-thrombin time, and of of bleeding according to bleeding of and OAC for emergency surgery of thromboembolic and bleeding risk of specific NOAC and dose dose function with estimated rate half-life of NOAC function and of anticoagulation or if not available pro-thrombin time, and of of bleeding according to bleeding of and OAC for emergency surgery of thromboembolic and bleeding risk non-vitamin K antagonist oral activated partial oral of patients with a major bleeding or requiring emergency surgery of specific NOAC and dose dose function with estimated rate half-life of NOAC function and of anticoagulation or if not available pro-thrombin time, and of of bleeding according to bleeding of and OAC for emergency surgery of thromboembolic and bleeding risk of specific NOAC and dose dose function with estimated rate half-life of NOAC function and of anticoagulation or if not available pro-thrombin time, and of of bleeding according to bleeding of and OAC for emergency surgery of thromboembolic and bleeding risk non-vitamin K antagonist oral activated partial oral coagulation tests are not for measuring reversal of NOAC effects vivo coagulation tests for the respective NOAC be CFCs be in case of life-threatening bleeding or emergency surgery in patients when a specific reversal is not available or there are of is no consistent effect of a specific CFC vivo studies and animal Pro-thrombin complex concentrates be over rFVIIa based on the pro-thrombotic the first reversal tested in critically patients, is in the effect of dabigatran by specific coagulation tests clinical and has been approved by the European Medicines Agency and the U.S. Food and Drug the effect of direct and FXa inhibitors and has been tested in so far. Ciraparantag is to direct and FXa inhibitors as well as In a Phase I was safe and well approved by regulatory the use of specific antidotes for NOACs be to life-threatening bleeding or emergency surgery. of NOACs may be sufficient due to their rather half-life for other situations requiring improved The effect of reversal agents on the clinical outcome in critically patients be assessed in controlled While specific antidotes for NOACs may not have an pro-thrombotic effect, the of anticoagulation in patients with a pro-thrombotic risk may thromboembolic events III The time of anticoagulation may therefore be for the clinical and the and of the for Supplementary is available at European of reports and support from from from and support from from the reports from the reports from from from from from from and the has to reports from from from from from from from the reports from from from from from from during the of the reports and from the has to reports and from and from from from the reports from from from during the of the from from from the reports from from from the reports from from from the reports and other from from from from The Medicines from and from from from from from and support from from the In has a to study results has as a for and and has been on the for and the reports from from from from during the of the has to
Language: English
Field: Medicine
Open Access status: bronze
OpenAlex ID: W2269729482
FWCI: 6.482
Cites: 64
Cited by: 65
Related to: 10